Your browser doesn't support javascript.
loading
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?
Fox, K A A; Eikelboom, J W; Anand, S S; Bhatt, D L; Bosch, J; Connolly, S J; Harrington, R A; Steg, P G; Yusuf, S.
Affiliation
  • Fox KAA; Centre for Cardiovascular Science, University of Edinburgh, 49 Little France Crescent, Edinburgh, UK.
  • Eikelboom JW; Population Health Research Institute, McMaster University and Hamilton Health Sciences, 237 Barton Street East, Hamilton ON, Canada.
  • Anand SS; Population Health Research Institute, McMaster University and Hamilton Health Sciences, 237 Barton Street East, Hamilton ON, Canada.
  • Bhatt DL; Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, 75 Francis Street, Boston, MA, USA.
  • Bosch J; Population Health Research Institute, McMaster University and Hamilton Health Sciences, 237 Barton Street East, Hamilton ON, Canada.
  • Connolly SJ; Population Health Research Institute, McMaster University and Hamilton Health Sciences, 237 Barton Street East, Hamilton ON, Canada.
  • Harrington RA; Stanford University, 300 Pasteur Dr, Stanford, CA, USA.
  • Steg PG; Assistance Publique-Hôpitaux de Paris, 3 Avenue Victoria, Paris, France.
  • Yusuf S; Population Health Research Institute, McMaster University and Hamilton Health Sciences, 237 Barton Street East, Hamilton ON, Canada.
Eur Heart J ; 40(18): 1466-1471, 2019 05 07.
Article in En | MEDLINE | ID: mdl-29945212
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vascular Diseases / Atherosclerosis / Secondary Prevention / Fibrinolytic Agents Limits: Humans Language: En Journal: Eur Heart J Year: 2019 Document type: Article Affiliation country: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vascular Diseases / Atherosclerosis / Secondary Prevention / Fibrinolytic Agents Limits: Humans Language: En Journal: Eur Heart J Year: 2019 Document type: Article Affiliation country: Reino Unido